Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a Healthcare company (Medical - Devices) with a market capitalization of $568M. The Maz Rating grades it against the other companies in its sector.
Pacific Biosciences of California, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.82, Pacific Biosciences of California, Inc. trades at 3.6x sales. Over the last twelve months it generated about $159M of revenue and a net loss of $129M. It runs a gross margin of 34.5%, an operating margin of -99.6% and a net margin of -81.3%. It shows return on equity of 604.2%, return on invested capital of -24.5% and a free cash flow yield of -33.1%. On the balance sheet: a debt-to-equity ratio of -11.49 and a current ratio of 4.62. Over the past 52 weeks the share price ranged from $1.07 to $3.44, with a beta of 2.20.
Pacific Biosciences of California, Inc. does not currently pay a dividend.
18 Wall Street analyst ratings cover the stock: 9 Buy, 8 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.